Evidence map›Paper›PMID 39741407›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

SINEUP RNA rescues molecular phenotypes associated with CHD8 suppression in autism spectrum disorder model systems.

Francesca Di Leva, Michele Arnoldi, Stefania Santarelli, Mathieu Massonot, Marianne Victoria Lemée, Carlotta Bon, Miguel Pellegrini, Maria Elena Castellini, Giulia Zarantonello, Andrea Messina and 11 more

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Francesca Di LevaNeuroEpigenetics Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy.
Michele ArnoldiNeuroEpigenetics Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy.
Stefania SantarelliNeuroEpigenetics Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy.
Mathieu MassonotUniversité de Strasbourg, CNRS, Inserm, IGBMC UMR 7104-UMR-S 1258, Department of Translational Medicine and Neurogenetics, 67404 Illkirch, France.
Marianne Victoria LeméeUniversité de Strasbourg, CNRS, Inserm, IGBMC UMR 7104-UMR-S 1258, Department of Translational Medicine and Neurogenetics, 67404 Illkirch, France.
Carlotta BonCenter for Human Technologies, Non-coding RNAs and RNA-based Therapeutics, Istituto Italiano di Tecnologia (IIT), 16152 Genova, Italy.
Miguel PellegriniNeuroEpigenetics Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy.
Maria Elena CastelliniNeural Development and Regeneration Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy.
Giulia ZarantonelloNeuroEpigenetics Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy.
Andrea MessinaNeural Development and Regeneration Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy.
Yuri BozziCenter for Mind/Brain Sciences - CIMeC, University of Trento, Rovereto, 38060 Trento, Italy.
Raphael BernierDepartment of Psychiatry and Behavioral Science, University of Washington School of Medicine, Seattle, WA 98195-6560, USA.
Silvia ZucchelliDepartment of Health Sciences and Research Center on Autoimmune and Allergic Diseases (CAAD), University of Piemonte Orientale (UPO), 28100 Novara, Italy.
Simona CasarosaNeural Development and Regeneration Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy.
Erik DassiLaboratory of RNA Regulatory Networks, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy.
Giuseppe RonzittiGenethon, 91000 Evry, France; Université Paris-Saclay, University Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France.
Christelle GolzioUniversité de Strasbourg, CNRS, Inserm, IGBMC UMR 7104-UMR-S 1258, Department of Translational Medicine and Neurogenetics, 67404 Illkirch, France.
Jasmin MorandellNeuroEpigenetics Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy. Electronic address: jasmin.morandell@unitn.it.
Stefano GustincichCenter for Human Technologies, Non-coding RNAs and RNA-based Therapeutics, Istituto Italiano di Tecnologia (IIT), 16152 Genova, Italy.
Stefano EspinozaCenter for Human Technologies, Non-coding RNAs and RNA-based Therapeutics, Istituto Italiano di Tecnologia (IIT), 16152 Genova, Italy; Department of Health Sciences and Research Center on Autoimmune and Allergic Diseases (CAAD), University of Piemonte Orientale (UPO), 28100 Novara, Italy. Electronic address: stefano.espinoza@uniupo.it.
Marta BiagioliNeuroEpigenetics Laboratory, Department of Cellular, Computational and Integrative Biology, University of Trento, 38123 Trento, Italy. Electronic address: marta.biagioli@unitn.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loss-of-function mutations in the chromodomain helicase DNA-binding 8 (CHD8) gene are strongly associated with autism spectrum disorders (ASDs). Indeed, the reduction of CHD8 causes transcriptional, epigenetic, and cellular phenotypic changes correlated to disease, which can be monitored in assessing new therapeutic approaches. SINEUPs are a functional class of natural and synthetic antisense long non-coding RNAs able to stimulate the translation of sense target mRNA, with no effect on transcription. Here, we employed synthetic SINEUP-CHD8 targeting the first and third AUG of the CHD8 coding sequence to efficiently stimulate endogenous CHD8 protein production. SINEUP-CHD8 were effective in cells with reduced levels of the target protein and in patient-derived fibroblasts with CHD8 mutations. Functionally, SINEUP-CHD8 were able to revert molecular phenotypes associated with CHD8 suppression, i.e., genome-wide transcriptional dysregulation, and the reduction of H3K36me3 levels. Strikingly, in chd8-morpholino-treated and ENU mutant zebrafish embryos, SINEUP-chd8 injection confirmed the ability of SINEUP RNA to rescue the chd8-suppression-induced macrocephaly phenotype and neuronal hyperproliferation. Thus, SINEUP-CHD8 molecule(s) represent a proof-of-concept toward the development of an RNA-based therapy for neurodevelopmental syndromes with implications for, and beyond ASD, and relevant to genetic disorders caused by protein haploinsufficiency.

Indexed as

Autism Spectrum DisorderDNA-Binding ProteinsRNA, Long NoncodingTranscription FactorsAnimalsDisease Models, AnimalHumansMutationPhenotypeZebrafishCHD8 protein, humanDNA-Binding ProteinsRNA, Long NoncodingTranscription FactorsASDautism spectrum disordersbrain disordersCHD8lncRNAneurodevelopmentRNA-based therapySINEUPtherapeutic treatmenttranslation activatorszebrafish

Identifiers

PMID39741407
PMCPMC11897779

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.